This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Lymphocytic Leukemia Clinical Trial

Official title:
A Randomized Phase 3 Study of Fludarabine and Rituximab With or Without Genasense® (Oblimersen Sodium) in Previously Untreated Subjects With Chronic Lymphocytic Leukemia

Status Withdrawn

Clinical Trial Summary

To compare the efficacy and safety of combination treatment with Genasense, fludarabine, and rituximab versus combination treatment with fludarabine and rituximab in previously untreated subjects with CLL.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00517218
Study type	Interventional
Source	Genta Incorporated
Contact
Status	Withdrawn
Phase	Phase 3
Start date	June 2006
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00609869` - Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab	Phase 2
Active, not recruiting	`NCT05065866` - Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy	Phase 1
Completed	`NCT00013533` - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies	Early Phase 1
Completed	`NCT02481297` - Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients	Phase 2
Completed	`NCT02434484` - Symbenda Post-Marketing Surveillance (PMS)
Completed	`NCT02556892` - A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 1
Completed	`NCT00935792` - Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Phase 1/Phase 2
Completed	`NCT02885038` - Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies	N/A
Completed	`NCT01499147` - Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies	N/A
Recruiting	`NCT03219450` - A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.	Phase 1
Recruiting	`NCT05272813` - A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL	Phase 1/Phase 2